337 related articles for article (PubMed ID: 16734505)
1. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
White S; Vender R; Thaçi D; Haverkamp C; Naeyaert JM; Foster R; Martinez Escribano JA; Cambazard F; Bibby A
Am J Clin Dermatol; 2006; 7(3):177-84. PubMed ID: 16734505
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
Kragballe K; Noerrelund KL; Lui H; Ortonne JP; Wozel G; Uurasmaa T; Fleming C; Estebaranz JL; Hanssen LI; Persson LM
Br J Dermatol; 2004 Jun; 150(6):1167-73. PubMed ID: 15214905
[TBL] [Abstract][Full Text] [Related]
3. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.
Cassano N; Miracapillo A; Coviello C; Loconsole F; Bellino M; Vena GA
Clin Drug Investig; 2006; 26(4):227-33. PubMed ID: 17163256
[TBL] [Abstract][Full Text] [Related]
4. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
Fleming C; Ganslandt C; Leese GP
J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
[TBL] [Abstract][Full Text] [Related]
7. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
8. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.
Kragballe K; Austad J; Barnes L; Bibby A; de la Brassinne M; Cambazard F; Fleming C; Heikkilä H; Williams Z; Peyri Rey J; Svensson A; Toole J; Wozel G
Dermatology; 2006; 213(4):319-26. PubMed ID: 17135738
[TBL] [Abstract][Full Text] [Related]
9. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
Kragballe K; Austad J; Barnes L; Bibby A; de la Brassinne M; Cambazard F; Fleming C; Heikkilä H; Jolliffe D; Peyri J; Svensson A; Toole J; Wozel G
Br J Dermatol; 2006 Jun; 154(6):1155-60. PubMed ID: 16704648
[TBL] [Abstract][Full Text] [Related]
10. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
Xia L; Li R; Wang Y; Lin Z; Zheng J; Li X; Lu Q; Zhang J; Jin H; Fu L; Zhang X; Liu Y; Yang S; Xiao F; Gao XH
Dermatol Ther; 2018 Sep; 31(5):e12632. PubMed ID: 30253049
[TBL] [Abstract][Full Text] [Related]
12. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
14. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.
Tyring S; Mendoza N; Appell M; Bibby A; Foster R; Hamilton T; Lee M
Int J Dermatol; 2010 Nov; 49(11):1328-33. PubMed ID: 20964660
[TBL] [Abstract][Full Text] [Related]
15. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
[TBL] [Abstract][Full Text] [Related]
16. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
Hashim PW; Nia JK; Terrano D; Goldenberg G; Kircik LH
J Drugs Dermatol; 2017 Aug; 16(8):747-752. PubMed ID: 28809989
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.
Guenther L; Van de Kerkhof PC; Snellman E; Kragballe K; Chu AC; Tegner E; Garcia-Diez A; Springborg J
Br J Dermatol; 2002 Aug; 147(2):316-23. PubMed ID: 12174105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
19. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study.
Fleming C; Ganslandt C; Guenther L; Johannesson A; Buckley C; Simon JC; Stegmann H; Vestergaard Tingleff L
Eur J Dermatol; 2010; 20(4):465-71. PubMed ID: 20413372
[TBL] [Abstract][Full Text] [Related]
20. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
Papp KA; Guenther L; Boyden B; Larsen FG; Harvima RJ; Guilhou JJ; Kaufmann R; Rogers S; van de Kerkhof PC; Hanssen LI; Tegner E; Burg G; Talbot D; Chu A
J Am Acad Dermatol; 2003 Jan; 48(1):48-54. PubMed ID: 12522370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
